Singapore, Nov. 3 -- Cambrex, a leading global contract development and manufacturing organisation (CDMO), has marked the groundbreaking of its $120 million expansion at its Charles City, Iowa facility, US.

The expansion will add 160,000 liters of manufacturing capacity, increasing the site's total capacity by approximately 25% to nearly one million liters, supporting the development and commercial manufacturing of small molecule active pharmaceutical ingredients (APIs) and synthetic peptides. The project is anticipated to be completed in the fourth quarter of 2028.

The Charles City facility provides development and manufacturing services for small molecule APIs, synthetic peptides and pharmaceutical intermediates, supporting projects f...